Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 305

1.

Publisher Correction: PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3.

Benitez JA, Ma J, D'Antonio M, Boyer A, Camargo MF, Zanca C, Kelly S, Khodadadi-Jamayran A, Jameson NM, Andersen M, Miletic H, Saberi S, Frazer KA, Cavenee WK, Furnari FB.

Nat Commun. 2018 May 25;9:16217. doi: 10.1038/ncomms16217.

PMID:
29799523
2.

MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells.

Talukdar S, Pradhan AK, Bhoopathi P, Shen XN, August LA, Windle JJ, Sarkar D, Furnari FB, Cavenee WK, Das SK, Emdad L, Fisher PB.

Proc Natl Acad Sci U S A. 2018 May 29;115(22):5768-5773. doi: 10.1073/pnas.1721650115. Epub 2018 May 14.

PMID:
29760085
3.

Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts.

Benitez JA, Zanca C, Ma J, Cavenee WK, Furnari FB.

J Vis Exp. 2018 Apr 26;(134). doi: 10.3791/57448.

PMID:
29757276
4.

FHL2 interacts with EGFR to promote glioblastoma growth.

Sun L, Yu S, Xu H, Zheng Y, Lin J, Wu M, Wang J, Wang A, Lan Q, Furnari F, Cavenee W, Purow B, Li M.

Oncogene. 2018 Mar;37(10):1386-1398. doi: 10.1038/s41388-017-0068-0. Epub 2018 Jan 11.

PMID:
29321665
5.

Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme.

Newman JP, Wang GY, Arima K, Guan SP, Waters MR, Cavenee WK, Pan E, Aliwarga E, Chong ST, Kok CYL, Endaya BB, Habib AA, Horibe T, Ng WH, Ho IAW, Hui KM, Kordula T, Lam PYP.

Nat Commun. 2017 Dec 4;8(1):1913. doi: 10.1038/s41467-017-01392-9.

6.

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.

Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD; GBM AGILE Network.

Clin Cancer Res. 2018 Feb 15;24(4):737-743. doi: 10.1158/1078-0432.CCR-17-0764. Epub 2017 Aug 16. Review.

PMID:
28814435
7.

Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses.

Teixeira AA, Marchiò S, Dias-Neto E, Nunes DN, da Silva IT, Chackerian B, Barry M, Lauer RC, Giordano RJ, Sidman RL, Wheeler CM, Cavenee WK, Pasqualini R, Arap W.

EMBO Mol Med. 2017 Oct;9(10):1327-1330. doi: 10.15252/emmm.201708072. No abstract available.

8.

Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity.

Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, Wu S, Yang H, Wykosky J, Frazer KA, Verkhusha VV, Isaguliants MG, Weiss WA, Gahman TC, Shiau AK, Chen CC, Mischel PS, Cavenee WK, Furnari FB.

Genes Dev. 2017 Jun 15;31(12):1212-1227. doi: 10.1101/gad.300079.117. Epub 2017 Jul 19.

9.

Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics.

Cai J, Lin Y, Zhang H, Liang J, Tan Y, Cavenee WK, Yan G.

Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):6812-6817. doi: 10.1073/pnas.1701002114. Epub 2017 Jun 12.

10.

PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3.

Benitez JA, Ma J, D'Antonio M, Boyer A, Camargo MF, Zanca C, Kelly S, Khodadadi-Jamayran A, Jameson NM, Andersen M, Miletic H, Saberi S, Frazer KA, Cavenee WK, Furnari FB.

Nat Commun. 2017 May 12;8:15223. doi: 10.1038/ncomms15223. Erratum in: Nat Commun. 2018 May 25;9:16217.

11.

Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling.

Liu F, Mischel PS, Cavenee WK.

NPJ Precis Oncol. 2017 Mar 20;1(1):1. doi: 10.1038/s41698-017-0005-2. eCollection 2017. Review.

12.

Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity.

Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee WK, Wechsler-Reya R, Furnari FB, Vandenberg SR, Rao PN, Wahl GM, Bafna V, Mischel PS.

Nature. 2017 Mar 2;543(7643):122-125. doi: 10.1038/nature21356. Epub 2017 Feb 8.

13.

Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.

Kegelman TP, Wu B, Das SK, Talukdar S, Beckta JM, Hu B, Emdad L, Valerie K, Sarkar D, Furnari FB, Cavenee WK, Wei J, Purves A, De SK, Pellecchia M, Fisher PB.

Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):370-375. doi: 10.1073/pnas.1616100114. Epub 2016 Dec 23.

14.

Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.

Chou ST, Patil R, Galstyan A, Gangalum PR, Cavenee WK, Furnari FB, Ljubimov VA, Chesnokova A, Kramerov AA, Ding H, Falahatian V, Mashouf L, Fox I, Black KL, Holler E, Ljubimov AV, Ljubimova JY.

J Control Release. 2016 Dec 28;244(Pt A):14-23. doi: 10.1016/j.jconrel.2016.11.001. Epub 2016 Nov 5.

15.

An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.

Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, Jenkins D, Martini M, Armando AM, Quehenberger O, Cloughesy TF, Furnari FB, Cavenee WK, Tontonoz P, Gahman TC, Shiau AK, Cravatt BF, Mischel PS.

Cancer Cell. 2016 Nov 14;30(5):683-693. doi: 10.1016/j.ccell.2016.09.008. Epub 2016 Oct 13.

16.

mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling.

Masui K, Shibata N, Cavenee WK, Mischel PS.

Bioessays. 2016 Sep;38(9):839-44. doi: 10.1002/bies.201600026. Epub 2016 Jul 18. Review.

17.

Cancer metabolism as a central driving force of glioma pathogenesis.

Masui K, Cavenee WK, Mischel PS.

Brain Tumor Pathol. 2016 Jul;33(3):161-8. doi: 10.1007/s10014-016-0265-5. Epub 2016 Jun 13. Review.

18.

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW.

Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9. Review.

PMID:
27157931
19.

Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.

Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, Li X, Bonetti B, Chopra R, James CD, Cavenee WK, Cloughesy TF, Mischel PS, Heath JR, Gini B.

Cancer Cell. 2016 Apr 11;29(4):563-573. doi: 10.1016/j.ccell.2016.03.012.

20.

mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment.

Masui K, Cavenee WK, Mischel PS.

Brain Pathol. 2015 Nov;25(6):755-9. doi: 10.1111/bpa.12307. Review.

21.

EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling.

Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, Barr CL, Furnari FB, Cloughesy TF, Yong WH, Gahman TC, Shiau AK, Cavenee WK, Ren B, Mischel PS.

Mol Cell. 2015 Oct 15;60(2):307-18. doi: 10.1016/j.molcel.2015.09.002. Epub 2015 Oct 8.

22.

Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.

Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9406-11. doi: 10.1073/pnas.1511759112. Epub 2015 Jul 13.

23.

PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.

Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8403-8. doi: 10.1073/pnas.1507882112. Epub 2015 Jun 15.

24.

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.

Shen Y, Li J, Nitta M, Futalan D, Steed T, Treiber JM, Taich Z, Stevens D, Wykosky J, Chen HZ, Carter BS, Becher OJ, Kennedy R, Esashi F, Sarkaria JN, Furnari FB, Cavenee WK, Desai A, Chen CC.

Oncotarget. 2015 May 20;6(14):11751-67.

25.

IGFBP2 potentiates nuclear EGFR-STAT3 signaling.

Chua CY, Liu Y, Granberg KJ, Hu L, Haapasalo H, Annala MJ, Cogdell DE, Verploegen M, Moore LM, Fuller GN, Nykter M, Cavenee WK, Zhang W.

Oncogene. 2016 Feb 11;35(6):738-47. doi: 10.1038/onc.2015.131. Epub 2015 Apr 20.

26.

Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma.

Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS.

Nat Rev Cancer. 2015 May;15(5):302-10. doi: 10.1038/nrc3918. Epub 2015 Apr 9. Review.

27.

Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance.

Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel PS.

Cancer Biol Med. 2014 Dec;11(4):255-63. doi: 10.7497/j.issn.2095-3941.2014.04.004. Review.

28.

Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy.

Chen K, Yang D, Li X, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H, Zhao Y, Zheng H, Li M, Buckner J, Patterson SD, Ye X, Reinhard C, Bhathena A, Joshi D, Mischel PS, Croce CM, Wang YM, Raghavakaimal S, Li H, Lu X, Pan Y, Chang H, Ba S, Luo L, Cavenee WK, Zhang W, Hao X.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1107-12. doi: 10.1073/pnas.1422640112. Epub 2015 Jan 12.

29.

A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.

Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK, Furnari FB.

Cancer Res. 2015 Jan 15;75(2):394-404. doi: 10.1158/0008-5472.CAN-14-2004. Epub 2014 Nov 28.

30.

Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.

Hu J, Muller KA, Furnari FB, Cavenee WK, VandenBerg SR, Gonias SL.

Oncogene. 2015 Jul 30;34(31):4078-88. doi: 10.1038/onc.2014.336. Epub 2014 Oct 27.

31.

EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.

Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK, Furnari FB, Cavenee WK, Hu B, Yan H, Cheng SY.

J Clin Invest. 2014 Sep;124(9):3741-56. doi: 10.1172/JCI73093. Epub 2014 Jul 25.

32.

Efficient synthesis of chloro-derivatives of sialosyllactosylceramide, and their enhanced inhibitory effect on epidermal growth factor receptor activation.

Kawashima N, Qu H, Lobaton M, Zhu Z, Sollogoub M, Cavenee WK, Handa K, Hakomori SI, Zhang Y.

Oncol Lett. 2014 Apr;7(4):933-940. Epub 2014 Feb 17.

33.

mTORC2 in the center of cancer metabolic reprogramming.

Masui K, Cavenee WK, Mischel PS.

Trends Endocrinol Metab. 2014 Jul;25(7):364-73. doi: 10.1016/j.tem.2014.04.002. Epub 2014 May 21.

34.

Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals.

Costa ET, Barnabé GF, Li M, Dias AA, Machado TR, Asprino PF, Cavalher FP, Ferreira EN, Del Mar Inda M, Nagai MH, Malnic B, Duarte ML, Leite KR, de Barros AC, Carraro DM, Chammas R, Armelin HA, Cavenee W, Furnari F, Camargo AA.

Oncogene. 2015 Mar 5;34(10):1270-9. doi: 10.1038/onc.2014.70. Epub 2014 Mar 24.

PMID:
24662834
35.

Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma.

Li J, Zhu S, Kozono D, Ng K, Futalan D, Shen Y, Akers JC, Steed T, Kushwaha D, Schlabach M, Carter BS, Kwon CH, Furnari F, Cavenee W, Elledge S, Chen CC.

Oncotarget. 2014 Feb 28;5(4):882-93.

36.

mTORC2 dictates Warburg effect and drug resistance.

Masui K, Cavenee WK, Mischel PS.

Cell Cycle. 2014;13(7):1053-4. doi: 10.4161/cc.28377. Epub 2014 Feb 28. No abstract available.

37.

Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity.

Gomez GG, Volinia S, Croce CM, Zanca C, Li M, Emnett R, Gutmann DH, Brennan CW, Furnari FB, Cavenee WK.

Cancer Res. 2014 Mar 1;74(5):1429-39. doi: 10.1158/0008-5472.CAN-13-2117. Epub 2014 Jan 16.

38.

Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.

Gomez GG, Wykosky J, Zanca C, Furnari FB, Cavenee WK.

Cancer Biol Med. 2013 Dec;10(4):192-205. doi: 10.7497/j.issn.2095-3941.2013.04.003. Review.

39.

Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.

Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Kornblum HI, Heath JR, Cavenee WK, Furnari FB, Mischel PS.

Science. 2014 Jan 3;343(6166):72-6. doi: 10.1126/science.1241328. Epub 2013 Dec 5.

40.

mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.

Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, Mellinghoff IK, Cavenee WK, Shaw RJ, Mischel PS.

Cell Metab. 2013 Nov 5;18(5):726-39. doi: 10.1016/j.cmet.2013.09.013. Epub 2013 Oct 17.

41.

The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.

Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS.

Clin Cancer Res. 2013 Oct 15;19(20):5722-32. doi: 10.1158/1078-0432.CCR-13-0527. Epub 2013 Sep 12.

42.

Glioblastoma: from molecular pathology to targeted treatment.

Cloughesy TF, Cavenee WK, Mischel PS.

Annu Rev Pathol. 2014;9:1-25. doi: 10.1146/annurev-pathol-011110-130324. Epub 2013 Aug 5. Review.

PMID:
23937436
43.

EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180.

Feng H, Hu B, Vuori K, Sarkaria JN, Furnari FB, Cavenee WK, Cheng SY.

Oncogene. 2014 May 8;33(19):2504-12. doi: 10.1038/onc.2013.198. Epub 2013 Jun 3.

44.

EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.

Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, Kurdistani SK, Eskin A, Nelson SF, Yong WH, Cavenee WK, Cloughesy TF, Christofk HR, Black DL, Mischel PS.

Cell Metab. 2013 Jun 4;17(6):1000-8. doi: 10.1016/j.cmet.2013.04.013. Epub 2013 May 23.

45.

Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.

Iwanami A, Cloughesy TF, Cavenee WK, Mischel PS.

Cell Cycle. 2013 May 15;12(10):1473-4. doi: 10.4161/cc.24747. Epub 2013 Apr 22. No abstract available.

46.

De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.

Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS.

Cancer Discov. 2013 May;3(5):534-47. doi: 10.1158/2159-8290.CD-12-0502. Epub 2013 Mar 26.

47.

A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma.

Read RD, Fenton TR, Gomez GG, Wykosky J, Vandenberg SR, Babic I, Iwanami A, Yang H, Cavenee WK, Mischel PS, Furnari FB, Thomas JB.

PLoS Genet. 2013;9(2):e1003253. doi: 10.1371/journal.pgen.1003253. Epub 2013 Feb 14.

48.

A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.

Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK.

Carcinogenesis. 2013 Apr;34(4):725-38. doi: 10.1093/carcin/bgt086. Epub 2013 Mar 1. Review.

49.

PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies.

Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, Toyama Y, Okano H, Mischel PS.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4339-44. doi: 10.1073/pnas.1217602110. Epub 2013 Feb 25.

50.

Genetic driver events in premalignancy: LOH validated for marking the risk of oral cancer.

Cavenee WK.

Cancer Prev Res (Phila). 2012 Sep;5(9):1073-4. doi: 10.1158/1940-6207.CAPR-12-0220. Epub 2012 Aug 21.

Supplemental Content

Loading ...
Support Center